


## PHARMACEUTICAL 2018



## Checkpoint Therapeutics Inc. Rank 226 of 342





## PHARMACEUTICAL 2018



## Checkpoint Therapeutics Inc. Rank 226 of 342

The relative strengths and weaknesses of Checkpoint Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Checkpoint Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Checkpoint Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is 23%, being 23% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	21,413
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,372
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	98
Other Revenues	1,725
Property and Equipment	0
Research and Development	19,081
Selling, General and Administrative Expense	5,419

Output Variable	Value in 1000 USD
Assets	21,413
Liabilities	6,372
Expenses	24,500
Revenues	1,725
Stockholders Equity	15,041
Net Income	-22,677
Comprehensive Net Income	-22,677
Economic Capital Ratio	23%

